VH-VL orientation prediction for antibody humanization candidate selection: A case study.
Alexander Bujotzek1, Florian Lipsmeier2, Seth F Harris3
1a Roche Pharmaceutical Research and Early Development, Large Molecule Research, Roche Innovation Center Penzberg , Nonnenwald 2, Penzberg , Germany.
Mabs
|December 5, 2015
Summary
Antibody humanization can be improved by selecting frameworks that maintain the 3D orientation of variable domains. This novel machine learning approach enhances antigen-binding affinity in humanized antibodies.
Area of Science:
- Immunology and Molecular Biology
- Biotechnology and Biopharmaceutical Development
Background:
- Antibody humanization grafts non-human antibody complementarity-determining regions onto human frameworks to reduce immunogenicity.
- Traditional humanization relies on sequence similarity for acceptor framework selection, potentially altering antigen-binding site geometry.
Purpose of the Study:
- To introduce a novel approach for antibody humanization focusing on preserving variable domain orientation.
- To improve the selection of acceptor frameworks by conserving the 3D geometry of the antigen-binding site.
Main Methods:
- Developed a machine learning-based predictor for antibody variable domain orientation.
- Selected acceptor frameworks based on conserved relative orientation between variable domains.
- Validated the approach using data from three humanization campaigns.
Main Results:
- Preselecting humanization variants based on predicted variable domain orientation significantly improved binding affinity.
- The novel method identified subsets of variants with enhanced antigen-binding capabilities compared to traditional methods.
Conclusions:
- Conserving variable domain orientation is a critical factor for successful antibody humanization.
- Machine learning-driven prediction of domain orientation offers a superior strategy for selecting humanization frameworks, leading to improved antibody efficacy.
Related Concept Videos
Antibody Structure
67.5K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
67.5K
Antibody Structure
15.1K
15.1K
Hybridoma Technology
18.5K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
18.5K
Antibody Structure and Classes
10.2K
Antibodies, also known as immunoglobulins, are produced by B cells in response to foreign substances, such as bacteria and viruses. These proteins are critical for recognizing and neutralizing these substances, protecting the body from potential harm.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
10.2K


